Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Spray LAIV Immunokinetics Study
NCT07545564Phase 4Enrolling by invitation
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of live attenuated influenza vaccine in influenza (2 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Membrane-specific sIgA antibody at 14 days. Started Apr 2026; status: enrolling by invitation.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07545564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545564.